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TABLE I. Demographic data and FLG genotype results for 71
volunteers with clinically normal skin
Sex 43 male/28 female
Age (y), range (median) 22-70 (41)
FLG wild-type subjects (no.) 61
FLG heterozygotes (no.) 10
Total (no.) 71
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that they have no relevant conflicts of interest.Volunteers were screened for the 6 most prevalent FLG loss-of-function mutations in
the population. Five subjects were heterozygous for R501X, 3 were heterozygous for
2282del4, 1 was heterozygous for R2447X, and 1 was heterozygous for S3247X. No
3673delC or 3702delG mutations were detected, and there were no homozygotes or
compound heterozygotes. Fitzpatrick skin phototype was recorded for 45 of 71
subjects, and there was no significant difference (P 5 .14, x2 test) in skin phototypes
between the genotype subgroups.REFERENCES
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determine the skin’s threshold to
UV-induced erythemaTo the Editor:
Profilaggrin and filaggrin play multiple roles in the formation
and function of the epidermal barrier, contributing to protection
against dehydration, mechanical stress, infection, and, it has been
proposed, photodamage.1 Loss-of-function mutations in the gene
encoding filaggrin (FLG) represent the strongest and most
significant genetic risk factor for atopic dermatitis (AD)
identified to date.1 Proteolysis of filaggrin releases histidine
and other amino acids into the stratum corneum. Histidine is
converted by the enzyme histidase (histidine ammonia-lyase)
to trans-urocanic acid (trans-UCA), which can then undergo
photoisomerization on absorption of UVB to produce cis-UCA
(see Fig E1 in this article’s Online Repository at www.
jacionline.org). There is experimental evidence to suggest that
cis-UCA has immunomodulatory and photoprotective effects. 2016 The Authors. Published by Elsevier, Inc. on behalf of the American Academy of
Allergy,Asthma& Immunology. This is an open access article under theCCBY license
(http://creativecommons.org/licenses/by/4.0/).The local and systemic immunosuppressive effects of cis-UCA
were initially demonstrated in murine models, and more recently,
histidinemic mice deficient in cutaneous UCA because of a
mutation in Hal, the gene encoding histidase, have been reported
to show increased propensity to UVB-induced DNA damage.2
Mice deficient in caspase-14 (an enzyme in the profilaggrin-
filaggrin proteolytic pathway) show accumulation of cyclobutane
pyrimidine dimers in response to UVB radiation and increased
apoptosis in the epidermis, indicating a role for caspase-14 in
UVB scavenging within the stratum corneum.3 The immunosup-
pressive effects of cis-UCA have been demonstrated in human
keratinocytes and leukocytes in vitro; knockdown of FLG in
organotypic culture results in increased susceptibility of kerati-
nocytes to UV-induced apoptosis.4 Loss-of-function mutations
and copy number variation in FLG are known to result in lower
levels of filaggrin breakdown products, including UCA, in human
stratum corneum. Therefore it has been postulated that FLG
genotype might in part determine the photoprotective capacity
of human skin (see Fig E1),1 but experimental evidence in vivo
is lacking.
We aimed to test the hypothesis that filaggrin deficiency
resulting from loss-of-function mutations in FLG is associated
with increased erythemal sensitivity to UV radiation. Cutaneous
response to UV radiation was assessed by using the minimal
erythema dose (MED; the lowest dose of UV causing just
perceptible skin redness) as a quantifiable surrogate end point
for cutaneous damage. We used detailed monochromator
phototesting of 71 adult volunteers of white European ethnicity
with clinically normal skin; the demographic characteristics are
summarized in Table I. A calculation performed before this study
commenced indicated that 7 or 8 FLG mutation carriers within a
total study size of 70 to 80 subjects would provide sufficient
statistical power to detect a 1.8-fold difference in MED. This
sample size estimation was based on known variability in
MEDs from previous studies and assuming comparisons of arith-
metic means of log-transformed data (therefore able to back–
transform differences into fold differences). Details of the power
calculation are shown in the Methods section in this article’s On-
line Repository at www.jacionline.org.
This work was approved by the East of Scotland Research
Ethics Committee (reference 14/ES/0030), and the study was
conducted in accordance with the Declaration of Helsinki.
Participants were screened for the 6 most prevalent loss-of-
function mutations in FLG in the white European population
(R501X, 2282del4, R2447X, S3247X, 3673delC, and
3702delG) by using published methodology.5 Ten (14%) of 71
FIG 1. Box plots showing monochromator phototesting MED results in healthy volunteers of different FLG
genotypes. The findings for 5 distinct wavebands are shown. Results for the 400 6 30 and 430 6 30 nm
wavebands showed no difference between FLG wild-type and heterozygotes (see Table E1); these data
are not displayed because the median MEDs and ranges are not quantifiable. Boxes indicate interquartile
ranges, and the bar within each box marks the median result. The difference in median MEDs (and 95%
CIs) are shown above each plot. All values are in millijoules per square centimeter. Median MEDs were
compared by using the Mann-Whitney U test. There were 61 FLG wild-type subjects and 10 FLG heterozy-
gous subjects tested in each group, with the exception of the 295 nm and 300 nmwavebands, in which data
were obtained on 53 FLG wild-type subjects and 8 FLG heterozygous subjects.
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FLG (Table I). Fitzpatrick sun-reactive skin phototype was
recorded for 45 of 71 subjects, and no difference was detected
(P 5 .14, x2 test) in skin phototypes between the genotype
subgroups.
Up to 7 separate wavebands from 295 to 430 nm, representing a
spectrum from UVB to UVA and visible light, were tested on the
71 subjects. A detailed description of phototesting methods is
given in the Methods section in this article’s Online Repository.
Subjects were grouped according to FLG genotype, and MEDs
were compared by using nonparametric rank-based methods
(because some MED values were greater than or less than test
dose ranges) with the Mann-Whitney U test (see the Methods
section in this article’s Online Repository) to derive CIs for
differences in medianMEDs (see Table E1 in this article’s Online
Repository at www.jacionline.org). We detected no significant
differences in MEDs (defined as P <_ .05) between the FLGwild-type and FLG heterozygous groups at any of the wavebands
tested (Fig 1 and see Table E1). The CIs for differences were suf-
ficiently narrow to make any large differences in MEDs between
the genotype groups unlikely.
It has previously been reported that AD might be associated
with photosensitivity,6 a lower threshold to UVB-induced ery-
thema,7 or both. Some epidemiologic data also suggest a higher
incidence of multiple nonmelanoma skin cancers in subjects
with a history of AD.8 Loss-of-function mutations in FLG are
strongly associated with AD, and there is widespread downregu-
lation of filaggrin expression in the skin of patients with atopic
eczema, which has been demonstrated at the transcriptome level
by means of direct RNA sequencing,9 and in the breakdown prod-
ucts of filaggrin in the stratum corneum, which was quantified by
means of HPLC.10 A partial reduction in expression of filaggrin
might result from the effect of circulating inflammatory
cytokines, whereas a more profound deficiency results from
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absence of profilaggrin in the homozygous or compound hetero-
zygous state. Therefore it can be hypothesized that filaggrin
deficiency contributes to the observed photosensitivity and/or
reduced threshold to UVB-induced erythema in patients with
AD. We have performed a detailed analysis of cutaneous
photoresponse in clinically normal skin to avoid the confounding
effects of atopic inflammation. Our findings have excluded a large
effect of FLG genotype on photosensitivity (>_1.8-fold difference
inMED) at any of thewavebands tested. In addition, the results of
our monochromator phototesting did not indicate a differential
erythemal sensitivity within the wavelengths representing UVB,
as would be predicted from the known absorption spectrum
of UCA.
One limitation of our study is that the healthy volunteers did not
include any subjects with ichthyosis vulgaris, and therefore we
have not excluded the possibility that FLG homozygous (or
compound heterozygous) subjects might show greater erythemal
sensitivity than wild-type subjects. However, FLG-null heterozy-
gosity has a significant effect on filaggrin expression in vivo,9,10
and therefore we would expect an effect to be observed in FLG
heterozygotes if this was substantial.
The fact that observations of UVB-induced damage in murine
and invitromodels have not been supported by clinical data suggest
that different mechanisms lead to cutaneous erythema in vivo than
the markers of UV damage studied in vitro and in mice. For
example, apoptosis is known to occur within areas of skin damaged
byUVexposure, and this is associatedwithcutaneous erythema, but
the relationship is nonlinear. Furthermore, the photoprotective
effect of the FLG wild-type genotype might be attributable to a
mechanical filtering of UV radiation by the stratum corneum rather
than by chemical photoimmunosuppression.
In conclusion, our FLG genotype–stratified analysis of
responses to UV and visible radiation in clinically normal skin
does not support the hypothesis that the breakdown products of
filaggrin play a major role in the sensitivity of human skin to
UV-induced erythema. This has relevance to the ongoing search
for predictors of patient response in phototherapy for AD and
for the development of personalized medicine.
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poietin predicts the development
of atopic dermatitis during infancyTo the Editor:
To establish a primary prevention strategy for atopic dermatitis
(AD), it is important to identify biomarkers that can predict the
occurrence of AD. This study aimed to evaluate the expression
level of epidermal proteins by using a tape stripping method to
determine whether these proteins can be used as biomarkers
predictive of AD development in infants.
In this prospective birth cohort study, we followed 75 infants in
a risk group and 12 in a control group for 2 years (Fig 1). The con-
trol group consisted of infants with both parents who had neither
allergy nor immediate skin test reactivity to 8 common inhalant
allergens (Dermatophagoides pteronyssinus, Dermatophagoides
farinae, tree pollen mixture _ & II, weed pollen mixture, grass
pollen mixture, cat, and cockroach). The risk group was defined
METHODS
Assessment of MEDs of different wavebands in
healthy volunteers
Healthy adults with clinically normal skin of phototypes I to IIIE1 who had
previously participated in research studies within the National Photobiology
Unit (Dundee, Scotland, United Kingdom) were invited to participate in this
study. Exclusion criteria were history of skin allergy, eczema/AD, psoriasis
or polymorphic light eruption, immunosuppression caused by medications
or disease, photosensitizing medication, and a holiday abroad or sunbed use
within the preceding 4 weeks. A total of 71 subjects providedwritten informed
consent and a saliva sample for DNA extraction. Emollient application to skin
test sites was not allowed within the 48 hours before phototesting.
Detailed phototesting was undertaken by using an irradiation mono-
chromator, which is a diffraction grating device with a 1.6-kW or 450-W
xenon arc lamp.E2,E3 This instrument allows irradiation of small areas of the
skin over a range of wavebands, which are included in the solar spectrum
(UVB to UVA/visible). Monochromator phototesting was performed as fol-
lows. On day 1, approximately 1-cm2 areas of the skin on the volunteer’s
back were exposed to UVand visible light according to a standardized proce-
dure established in the National Photobiology Unit. A range of doses of UV
and visible light at specific narrow wavebands was used for all subjects
centered on (with half-maximum bandwidth) 295 6 5, 300 6 5, 305 6 5,
335 6 30, 365 6 30, 400 6 30, and 430 6 30 nm.
The MED, which was defined as the minimum dose producing just
perceptible erythema for each waveband tested, was determined 24 hours after
irradiation. The irradiation procedurewas repeated on day 2 on a separate area
of back skin using smaller dose increments (10% to 20%) across a narrower
range of doses at each waveband selected on the basis of the MEDs seen
24 hours after first irradiation to establish the MED precisely. Final MEDs
were assessed 24 hours later (day 3).
Power calculation
Our prestudy sample size calculation was performed to determine
how many subjects were likely to be needed to detect a clinically
important difference in MEDs between the FLG genotype groups within the
305 6 30 nm waveband. MED data derived from testing with a geometric
dose series do not follow a normal distribution, and therefore we based our
sample size on the minimum difference in arithmetic means of natural log-
transformed MEDs. This method was used because differences in arithmetic
means of log-transformed data can be ‘‘back-transformed’’ to fold
differences (eg, 1.8-fold), which is more understandable than the difference
in log-transformed MEDs that equates to this.
MEDs for the 305 6 5 nm waveband (representing a narrow waveband in
the UVB region, the waveband of interest) from 120 healthy volunteers tested
at the National Photobiology Unit were used to derive variance. These
nonnormal datawere log-transformed, and the numbers needed to detect a 1.5-,
1.8-, and 2-fold difference in geometric means were estimated by using Stata
12.1 software (StataCorp, College Station, Tex). Assuming that approximately
10% of the study participants would have 1 or more FLG loss-of-function mu-
tations,E4 to obtain an 80%powerwith aP value of .05,we required at least 7 or
8 subjects with FLG mutations (expected within a total sample size of 70-80
subjects) to detect a difference of 1.8-fold in mean natural log-transformed
MEDs at this waveband between the wild-type and FLG-null groups. Simi-
larly, 55 volunteers, including 5 or 6 FLG mutation carriers, were needed to
detect a 2-fold difference in mean natural log-transformed UVB MEDs.
Therefore the results arising from our sample size, including 71 volunteers
and 10 FLG mutation carriers, have sufficient statistical power to effectively
exclude an association with FLG genotype and erythemal response of a
1.8-fold or greater difference at the wavebands tested.
Statistical analysis of monochromator phototesting
data
When analyzing our data, we used nonparametric methods reliant on ranks,
rather than absolute values, instead of parametric methods based on trans-
formed data. This was for the practical reason that although we obtained ranks
for all MEDs, the precise values for some were unknown (greater than or less
than our test dose range). Some MEDs were determined to be greater than or
less than the test irradiation ranges. A small number was added to all MEDs at
greater than the top dose tested for wavebands of 305 nm and longer and a
small number was subtracted fromMEDs of less than the lowest dose tested to
allow appropriate rank-based analyses. The phototesting results were
compared with FLG genotype status (FLGwild-type or FLGmutant) by using
the Mann-Whitney U test to analyze these nonparametric data to test the null
hypothesis that therewas no association ofMEDswith genotype. Correspond-
ing CIs around medians were derived by using the methods of Altman and
Gardner.E5 We took a P value of .05 or less to be significant.
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FIG E1. Diagrammatic summary of factors affecting the profilaggrin–cis-UCA pathwayPrevious studies
have demonstrated the effects of variation within FLGE6-E8 and levels of TH2 cytokines
E9,E10 on filaggrin
expression. The role of caspase-14 in profilaggrin processing has been illustrated in mice.E11 Filaggrin is
degraded to release a pool of amino acids rich in histidineE12 in the stratum corneum, contributing to barrier
function through hydration and acidification.E13 The conversion of histidine to trans-UCA is catalyzed by
histidase,E14 and the trans-isomer is converted to cis-UCA by UVB.E15 UVB absorption might contribute
to cutaneous photoprotection, and cis-UCA might have additional immunomodulatory effects.E16-E20
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TABLE E1. Results of monochromator phototesting of 71 healthy volunteers stratified according to FLG genotype
Waveband
295 6 5 nm 300 6 5 nm 305 6 5 nm 335 6 30 nm 365 6 30 nm 400 6 30 nm 430 6 30 nm
Median MED (mJ/cm2)
FLG wild-type
subjects
10.0 (n 5 53) 18.0 (n 5 53) 47.0 (n 5 61) 5,600 (n 5 61) 24,000 (n 5 61) >82,000 (n 5 61) >82,000 (n 5 61)
FLG heterozygous
subjects
8.2 (n 5 8) 15.0 (n 5 8) 47.0 (n 5 10) 4,950 (n 5 10) 20,000 (n 5 10) 82,000 (n 5 10) >82,000 (n 5 10)
Difference 1.8 mJ/cm2
higher in
FLG wild-type
3.0 mJ/cm2
higher in
FLG wild-type
No difference 650 mJ/cm2
higher in FLG
wild-type
4,000 mJ/cm2
higher in FLG
wild-type
Not quantifiable Not quantifiable
95% CI for
difference
22.6 to 5.0 23.0 to 7.0 29.0 to 14.0 21,200 to 2,300 27,000 to 9,000 Not quantifiable Not quantifiable
P value (Mann-
Whitney U test)
.41 .35 .79 .62 .74 .58 .70
Some cells are ‘‘not quantifiable’’ because results of greater than the highest test dose were recorded.
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